Low IL-1α expression in bladder cancer tissue and survival

European Urology

Volumn 43, Issue 4, 2003, Pages 362-368

  Seddighzadeh, M ^a   Larsson, P ^a   Ulfgren, A C ^a   Onelov E ^a   Berggren, P ^a   Tribukait, B ^a   Torstensson, A ^a   Norming, U ^b   Wijkstrom H ^c   Linder, S ^a   Steineck, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Interleukin 1 ; Survival; Urinary bladder cancer

Indexed keywords

INTERLEUKIN 1ALPHA; MESSENGER RNA; INTERLEUKIN 1;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DISEASE ASSOCIATION; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STROMA CELL; TUMOR CELL; BLADDER TUMOR; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SURVIVAL; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SWEDEN; URINARY BLADDER NEOPLASMS;

EID: 0043261443     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00047-2     Document Type: Article

References (32)

1. Apte RN. Mechanisms of cytokine production by fibroblasts -implications for normal connective tissue homeostasis and pathological conditions. Folia Microbiol 1995;40:392-404.
2. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
4. Lachman LB, Dinarello CA, Llansa ND, Fidler IJ. Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. J Immunol 1986;136:3098-102.
5. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985;135(6):3962-8.
6. Paciotti GF, Tamarkin L. Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol Endocrinol 1988;2:459-64.
7. Muegge K, Williams TM, Kant J, et al. Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science 1989;246:249-51.
8. Cozzolino F, Torcia M, Aldinucci D, et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA 1990;87:6487-91.
9. Janik JE, Miller LL, Longo DL, et al. Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996;88:44-9.
10. Kitamura K. Clinical application of new cytokines. Rinsho Byori 1993;41:390-8.
11. Smith 2nd JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10:1141-52.
12. Verschraegen CF, Kudelka AP, Termrungruanglert W, et al. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer 1996;32A:1609-11.
13. Seddighzadeh M, Steineck G, Jansson O, et al. Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma. Br J Cancer 2001;84:329-34.
14. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of 8 years. Acta Chirurg Scand 1965;130:371-8.
15. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 1991;119:65-93.
16. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
17. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
18. Andersson J, Abrams J, Bjork L, et al. Concomitant in vivo production of 19 different cytokines in human tonsils. Immunology 1994;83:16-24.
19. Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 1995;63:289-96.
20. Seddighzadeh M, Steineck G, Larsson P, et al. Urokinase and its receptor and the clinical course of urinary bladder neoplasms. Int J Cancer 2002;99:721-6.
21. Wada T, Louhelainen J, Hemminki K, et al. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 2000;6(2):610-5.
22. Berggren P, Steineck G, Adolfsson J, et al. p53 mutations in urinary bladder cancer. Br J Cancer 2001;84:1505-11.
23. Hayashi O, Akashi M, Fujime M, Hanazawa K, Kitagawa R. Detection of interleukin-1 activity in human bladder cancer cell lines. J Urol 1994;151:750-3.
24. Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin. J Urol 1996;156:536-41.
25. Bereta M, Bereta J, Cohen S, Zaifert K, Cohen MC. Effect of inflammatory cytokines on the adherence of tumor cells to endothelium in a murine model. Cell Immunol 1991;136(2):263-77.
26. Giavazzi R, Garofalo A, Bani MR, et al. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 1990;50(15):4771-5.
27. Sawai H, Yamamoto M, Okada Y, et al. Alteration of integrins by interleukin-1alpha in human pancreatic cancer cells. Pancreas 2001;23(4):399-405.
28. Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 1992;51(5):822-30.
29. Apte RN, Dvorkin T, Song X, et al. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol 2000;479:277-88.
30. Voronov E, Weinstein Y, Benharroch D, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999;59(5):1029-35.
31. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast. Br J Cancer 1998;78(6):788-94.
32. Castro J, Heiden T, Wang N, Tribukait B. Preparation of cell nuclei from fresh tissues for high-quality DNA flow cytometry. Cytometry 1993;14(7):793-804.